Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant–associated thrombotic microangiopathy?

Authors

  • Sonata Jodele,

    Corresponding author
    1. From the Division of Bone Marrow Transplantation and Immune Deficiency, the Division of Nephrology and Hypertension, and the Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center; and Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio.
    Search for more papers by this author
  • Benjamin L. Laskin,

    1. From the Division of Bone Marrow Transplantation and Immune Deficiency, the Division of Nephrology and Hypertension, and the Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center; and Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio.
    Search for more papers by this author
  • Jens Goebel,

    1. From the Division of Bone Marrow Transplantation and Immune Deficiency, the Division of Nephrology and Hypertension, and the Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center; and Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio.
    Search for more papers by this author
  • Jane C. Khoury,

    1. From the Division of Bone Marrow Transplantation and Immune Deficiency, the Division of Nephrology and Hypertension, and the Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center; and Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio.
    Search for more papers by this author
  • Susan L. Pinkard,

    1. From the Division of Bone Marrow Transplantation and Immune Deficiency, the Division of Nephrology and Hypertension, and the Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center; and Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio.
    Search for more papers by this author
  • Patricia M. Carey,

    1. From the Division of Bone Marrow Transplantation and Immune Deficiency, the Division of Nephrology and Hypertension, and the Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center; and Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio.
    Search for more papers by this author
  • Stella M. Davies

    1. From the Division of Bone Marrow Transplantation and Immune Deficiency, the Division of Nephrology and Hypertension, and the Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center; and Hoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio.
    Search for more papers by this author

  • The Cincinnati Children's Hospital and Medical Center Institutional Review Board exempted this study from obtaining informed consent from the patient and family.

Sonata Jodele, MD, Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 7015, Cincinnati, OH 45229; e-mail sonata.jodele@cchmc.org.

Abstract

BACKGROUND: The use of therapeutic plasma exchange (TPE) in hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) is controversial because the exact mechanism of injury in TA-TMA is not yet understood.

STUDY DESIGN AND METHODS: The study objective was to retrospectively review the outcome of children receiving TPE for TA-TMA at our institution. We hypothesized that patients initiating TPE earlier in their disease course would receive a greater benefit than those starting later, regardless of the therapeutic mechanism.

RESULTS: We identified 10 consecutive pediatric patients with TA-TMA treated with TPE. Nine of these patients showed normalization of the laboratory variables associated with microangiopathy during their TPE course, but only five patients recovered renal function and survived TA-TMA. The five survivors started TPE a median of 17 days (range, 4-25 days) after TA-TMA diagnosis while the five patients who died started TPE a median of 32 days (range, 17-73 days) after TA-TMA was diagnosed. Three of the five survivors had multiorgan failure at TA-TMA diagnosis and completely recovered with early institution of TPE. These three survivors were able to discontinue renal replacement therapy, and all achieved a normal posttreatment creatinine. The five patients with later institution of TPE progressed to end-stage renal disease and all died. There were no serious TPE-related complications in either group.

CONCLUSION: This is the first report evaluating TPE response in regard to procedure initiation time after TA-TMA diagnosis. Our data suggests that early initiation of TPE might be beneficial even in patients with multiorgan failure due to TA-TMA.

Ancillary